Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer

Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer

Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at a dose of 130 mg/m2/day orally for 10 days every 6 weeks. Only one patient, with nodal and chest wall metastases, had a sustained complete r...

Full description

Saved in:
Bibliographic Details
Published in:Cancer treatment reports Vol. 68; no. 12; p. 1499
Main Authors: Creech, R H, Catalano, R B, Dierks, K M, Shah, M K
Format: Journal Article
Language:English
Published: United States 01-12-1984
Subjects:
Adult
Aged
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast Neoplasms - drug therapy
Cyclophosphamide - administration & dosage
Drug Evaluation
Female
Fluorouracil - administration & dosage
Humans
Methotrexate - administration & dosage
Middle Aged
Mitolactol - therapeutic use
Mitolactol - toxicity
Neoplasm Metastasis
Receptors, Estrogen - analysis
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at a dose of 130 mg/m2/day orally for 10 days every 6 weeks. Only one patient, with nodal and chest wall metastases, had a sustained complete regression; two patients had stable disease; and 35 patients had disease progression. The toxicity, which was primarily hematologic, was acceptable.
ISSN:0361-5960